Mars Inc. completes VCA Inc. acquisitionSeptember 12, 2017What started in January is a done deal, as Mars Inc. has announced that its acquisition of VCA Inc. is now complete. VCA will operate as a distinct and separate business within Mars Petcare, alongside Banfield Pet Hospital, BluePearl Veterinary Partners, and Pet Partners. Bob Antin, co-founder and CEO of VCA animal hospitals, will remain at the helm at its Los Angeles headquarters. "I welcome the 25,000-plus VCA team members to the Mars Petcare family of companies," said Poul Weihrauch, president of Mars Global Petcare. "VCA's partnerships with veterinarians and pet care providers, as well as their breadth and expertise in veterinary services, diagnostics and technology, will position all of us to deliver more comprehensive care and continue on our journey supporting our purpose: a better world for pets." Mars, which reports approximately $35 billion in sales per year and operates in more than 80 countries, produces Pedigree, Royal Canin, and Whiskas pet food brands, in addition to owning Banfield, BluePearl, and Pet Partners. VCA delivers pet health care services through more than 800 small animal veterinary hospitals in the U.S. and Canada; Antech Diagnostics, a nationwide clinical laboratory system that services all 50 states and Canada; animal diagnostic …
SPONSORED CONTENTDon't just protect. Triple protect.Replace two products with one convenient monthly chew. + See the difference
Henry Schein to acquire Merritt Veterinary Supplies, expand U.S. presenceAugust 30, 2017Henry Schein Inc., a provider of health care products and services to animal health practitioners, announced its plans to acquire Merritt Veterinary Supplies Inc., a family-owned supplier of animal health products. Merritt serves approximately 4,500 veterinary clinics across the eastern U.S.
Zoetis completes acquisition of Nexvet BiopharmaAugust 8, 2017Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.
Zoetis to acquire Nexvet Veterinary Biologic Therapeutics Co.April 13, 2017Zoetis Inc. announced it will purchase Nexvet Biopharma veterinary biologic therapeutics company for US $6.72 per share, or a valuation of approximately US $85 million. Pending approval, the purchase is expected to be completed during the second half of 2017.
Mars to buy VCA clinics, labs in $9.1 billion dealJanuary 9, 2017Mars Inc. has agreed to acquire VCA Inc., which operates one of North America’s largest veterinary hospital chains, in a transaction valued at $9.1 billion, the companies announced today.
